Moderna will apply for extraordinary approval of his vaccine in the USA and the European Union

“I have to say that the data looks very good indeed,” said Paul Offit, a member of the FDA’s advisory committee. In addition, according to data and analyzes, the vaccine can prevent severe covid-19 disease with 100% efficacy.

“We believe that our vaccine can completely change the course of the whole pandemic. It will prevent serious processes, hospitalizations and, above all, deaths, “said Moderna CEO Stéphane Bancel.

The chief physician of the pharmaceutical company Tal Zaks even admitted that he cried after analyzing the data.

One of the more expensive ones

Moderna will fill out an official application for extraordinary use of its vaccine at the FDA during Monday. It has also provided data to several other regulatory authorities around the world, where it will also seek to deploy the drug.

The vaccine from Moderna will be among the more expensive. Bancel told the German newspaper Welt am Sonntag that the price of the benefit should range from 10 to 50 dollars (220 to 1100 crowns). According to the Observer, the European Union is trying to negotiate so that the price in the 27 countries does not exceed $ 25 (less than 550 crowns).

Moderna is the second company to apply for special approval for its vaccine. Ten days ago, Pfizer, which is developing the vaccine in collaboration with Germany’s BioNTech, did the same. The FDA will review both applications in December, so the vaccine could enter circulation early next year.

Share on facebook
Share on pinterest
Share on twitter
Share on linkedin
Share on email


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.